Safety and efficacy of BAY 81‐8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme-Reference-Cited by-同舟云学术

Safety and efficacy of BAY 81‐8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme

Author:

Oldenburg J.¹,Windyga J.²,Hampton K.³,Lalezari S.⁴,Tseneklidou‐Stoeter D.⁵,Beckmann H.⁶,Maas Enriquez M.⁶

Affiliation:

1. University Clinic Bonn Bonn Germany

2. Institute of Hematology and Transfusion Medicine Warsaw Poland

3. Sheffield Haemophilia and Thrombosis Center Sheffield UK

4. National Hemophilia Center Chaim Sheba Medical Center Tel Hashomer Israel

5. Bayer Pharma AG BerlinGermany

6. Bayer Pharma AG Wuppertal Germany

Funder

Bayer HealthCare

Publisher

Wiley

Subject

Genetics(clinical),Hematology,General Medicine

Link

Reference12 articles.

3. BAY 81‐8973 – a new full‐length recombinant FVIII product using novel manufacturing technologies;Vogel JH;Haemophilia,2010

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献